Literature DB >> 33145987

Survival trends and prognostic factors in patients with solitary plasmacytoma of bone: A population-based study.

Xuxing Shen1, Shu Liu2, Chao Wu1, Jing Wang1, Jianyong Li1, Lijuan Chen1.   

Abstract

Solitary plasmacytoma of bone (SPB) is a single, isolated plasmacytoma originated from the bone. The survival trends of patients with SPB in recent years remain unknown. And the prognostic system of SPB may also need to be refined. The 18 Surveillance, Epidemiology, and End Results (SEER) databases of the National Cancer Institute in the United States were used to extract data for this study. The third edition of the International Classification of Disease for Oncology (ICD-O-3) code 9731 was used to identify cases of SPB. For each case, factors including age at the time of diagnosis, sex, race, marital status, insurance status, primary sites of tumors, and the use of surgery were collected. The outcomes of patients with SPB were compared between two groups. And the prognostic impacts of baseline characteristics and use of surgery was studied. A total of 4103 (from 1976 to 2016) cases of SPB were identified. The median age was 65 years old. Patients in time period-2 (2008-2016) show better survival as compared to those in time period-1(1976-2007) (median overall survival: 88 months vs. 73 months, p = 0.0332). Age ≤ 65 years and being male were associated with better outcomes. The widowed individuals had significantly inferior survival and myeloma-specific survival than the single, married, or divorced individuals (p values all <0.0001). Patients with lesions in bones of skull and face and associated joints had longer survival as compared with those with bone lesions in other sites (median overall survival: 107 months vs. 79 months, p = 0.0694). The use of surgery was significantly associated with improved survival (median survival: surgery performed 98 months vs. not performed 73 months, hazards ratio [HR]: 0.7623, 95% CI: 0.7009-0.8472; p < 0.0001) and myeloma-specific survival (median myeloma-specific survival: surgery 160.0 months vs. no surgery 143.0 months, HR: 0.8469, 95% CI: 0.7493-0.9572; p = 0.0078). Multivariable analysis revealed that surgery, marital status, and age were independent prognostic factors for overall survival in patients with SPB. The improvement in the survival of patients with SPB has been observed in recent years. And several potential prognostic factors were identified. Future prospective studies are warranted to explore the roles of novel agents, surgery, and systemic chemotherapy in the treatment of SPB.
© 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

Entities:  

Keywords:  prognostic factor; solitary plasmacytoma of bone; survival trends

Mesh:

Year:  2020        PMID: 33145987      PMCID: PMC7877371          DOI: 10.1002/cam4.3533

Source DB:  PubMed          Journal:  Cancer Med        ISSN: 2045-7634            Impact factor:   4.452


  24 in total

1.  Prognostic factors influencing survival in solitary plasmacytoma.

Authors:  Giridharan Ramsingh; Paul Mehan; Daniel Morgensztern; Jingqin Luo; Ravi Vij
Journal:  Br J Haematol       Date:  2008-03-02       Impact factor: 6.998

Review 2.  Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group.

Authors:  Michele Cavo; Evangelos Terpos; Cristina Nanni; Philippe Moreau; Suzanne Lentzsch; Sonja Zweegman; Jens Hillengass; Monika Engelhardt; Saad Z Usmani; David H Vesole; Jesus San-Miguel; Shaji K Kumar; Paul G Richardson; Joseph R Mikhael; Fernando Leal da Costa; Meletios-Athanassios Dimopoulos; Chiara Zingaretti; Niels Abildgaard; Hartmut Goldschmidt; Robert Z Orlowski; Wee Joo Chng; Hermann Einsele; Sagar Lonial; Bart Barlogie; Kenneth C Anderson; S Vincent Rajkumar; Brian G M Durie; Elena Zamagni
Journal:  Lancet Oncol       Date:  2017-04       Impact factor: 41.316

3.  Persistence of myeloma protein for more than one year after radiotherapy is an adverse prognostic factor in solitary plasmacytoma of bone.

Authors:  Richard B Wilder; Chul S Ha; James D Cox; Donna Weber; Kay Delasalle; Raymond Alexanian
Journal:  Cancer       Date:  2002-03-01       Impact factor: 6.860

Review 4.  Solitary Plasmacytoma: a Review of Diagnosis and Management.

Authors:  Andrew Pham; Anuj Mahindra
Journal:  Curr Hematol Malig Rep       Date:  2019-04       Impact factor: 3.952

5.  Solitary bone plasmacytoma: outcome and prognostic factors following radiotherapy.

Authors:  R H Liebross; C S Ha; J D Cox; D Weber; K Delasalle; R Alexanian
Journal:  Int J Radiat Oncol Biol Phys       Date:  1998-07-15       Impact factor: 7.038

Review 6.  A review for solitary plasmacytoma of bone and extramedullary plasmacytoma.

Authors:  Sevil Kilciksiz; Omur Karakoyun-Celik; Fulya Yaman Agaoglu; Ayfer Haydaroglu
Journal:  ScientificWorldJournal       Date:  2012-05-02

7.  Prognostic factors in solitary plasmacytoma of the bone: a multicenter Rare Cancer Network study.

Authors:  David Knobel; Abderrahim Zouhair; Richard W Tsang; Philip Poortmans; Yazid Belkacémi; Michel Bolla; Fazilet Dinçbas Oner; Christine Landmann; Bernard Castelain; Mahmut Ozsahin
Journal:  BMC Cancer       Date:  2006-05-05       Impact factor: 4.430

Review 8.  Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond.

Authors:  C S Chim; S K Kumar; R Z Orlowski; G Cook; P G Richardson; M A Gertz; S Giralt; M V Mateos; X Leleu; K C Anderson
Journal:  Leukemia       Date:  2017-11-16       Impact factor: 11.528

9.  Impact of radiation dose on local control and survival in extramedullary head and neck plasmacytoma.

Authors:  Michael Oertel; Khaled Elsayad; Kai Jannes Kroeger; Uwe Haverkamp; Claudia Rudack; Georg Lenz; Hans Theodor Eich
Journal:  Radiat Oncol       Date:  2019-04-15       Impact factor: 3.481

Review 10.  Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel.

Authors:  J Caers; B Paiva; E Zamagni; X Leleu; J Bladé; S Y Kristinsson; C Touzeau; N Abildgaard; E Terpos; R Heusschen; E Ocio; M Delforge; O Sezer; M Beksac; H Ludwig; G Merlini; P Moreau; S Zweegman; M Engelhardt; L Rosiñol
Journal:  J Hematol Oncol       Date:  2018-01-16       Impact factor: 17.388

View more
  4 in total

1.  Prediction of Solitary Plasmacytoma of Bone in Elderly Patients: A Nomogram and a Risk Classification System for Overall Survival.

Authors:  Xi Zhang; Jiahao Yang; Zhuanhua Tian; Youssef Khabir; Dan Wang
Journal:  Biomed Res Int       Date:  2022-06-01       Impact factor: 3.246

Review 2.  Pathological axis fracture secondary to a solitary bone plasmacytoma: Two cases and a literature review.

Authors:  Ratko Yurac; Alvaro Silva; Matias Delgado; Marilaura Nuñez; Juan Lopez; Bartolome Marre
Journal:  Surg Neurol Int       Date:  2021-04-14

3.  A Rare Case of Solitary Plasmacytoma Arising From the Sternum.

Authors:  Nyan Bethel; Henna Asrar; Jenna Dacosta; Andreas Savopoulos; Hamid Shaaban
Journal:  Cureus       Date:  2022-04-04

4.  A new prediction model for overall survival of elderly patients with solitary bone plasmacytoma: A population-based study.

Authors:  Yingying Wu; Jiemin Wei; Shaomei Chen; Xiaozhu Liu; Junyi Cao
Journal:  Front Public Health       Date:  2022-09-13
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.